Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
火曜日, 9 08

Bristol-Myers Squibb Co

BMYNYSE
Trade with Public
Trade with Public
$66.82
-1.27-1.87%
近くで: Sep 4, 5:00 PM EST
$66.83
0.010.01%
時間外: Sep 4, 5:51 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Bristol-Myers Squibb Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bristol-Myers Squibb (BMY).

Price Target Range — 13 Quarters

Analyst Consensus — 24 Analysts

10Buy
13Hold
1Sell
Consensus RatingNeutral# Analysts24Avg. Consensus PT$62Upside to Avg. PT-6.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026Argus ResearchJasper HellwegUpgradeHold→Buy$75
Aug 3, 2026CitigroupGeoff MeachamPT RaiseNeutral$66→$70
More with Benzinga EdgeGet Access

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Avi Kapoor

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.
Vandana Singh

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
Avi Kapoor

PRO
Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy and announces $75 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $66 to $70.
Benzinga Newsdesk

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
Vandana Singh

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved